<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Nalidixic Acid</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00779</strong>&#160; (APRD01133)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial <span class="caps">DNA</span> gyrase. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00779/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00779/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00779.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00779.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00779.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00779.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00779.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00779">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Acide nalidixique</td><td>French</td><td>INN</td></tr><tr><td>Acido nalidixico</td><td>Spanish</td><td>INN</td></tr><tr><td>Acidum Nalidixicum</td><td>Latin</td><td>INN</td></tr><tr><td>Nalidixins&#228;ure</td><td>German</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Adix</td><td>Nenza Pharma</td></tr><tr><td>Curiemylon</td><td>Panion &amp; BF</td></tr><tr><td>Degram</td><td>Doctor's Chemical Works</td></tr><tr><td>Delugi</td><td>Washington</td></tr><tr><td>Dixicon</td><td>Jayson</td></tr><tr><td>Glanega</td><td>Meider</td></tr><tr><td>Gramazine</td><td>Johnson</td></tr><tr><td>Gramoneg</td><td>Ranbaxy</td></tr><tr><td>Huei Yi</td><td>Chen Ho</td></tr><tr><td>Lisalenb</td><td>San Tong</td></tr><tr><td>Litalon</td><td>Li Ta</td></tr><tr><td>Nadixin</td><td>Pei Jin</td></tr><tr><td>Nadon</td><td>Century</td></tr><tr><td>Nagomin</td><td>Ming Ta</td></tr><tr><td>Nal-acid</td><td>Farmanic Chemipharma</td></tr><tr><td>Nalic</td><td>Yu Sheng</td></tr><tr><td>Nalicid</td><td>Torrent</td></tr><tr><td>Nalid</td><td>Square</td></tr><tr><td>Nalidin</td><td>Fu Yuan</td></tr><tr><td>Nalidix</td><td>Dar-Al-Dawa</td></tr><tr><td>Naligram</td><td>Acme</td></tr><tr><td>Nalitomylon</td><td>The Central</td></tr><tr><td>Nalix</td><td>Aristopharma</td></tr><tr><td>Nalixid</td><td>Zentiva</td></tr><tr><td>Nalixin</td><td>Yung Sine</td></tr><tr><td>Nebactil</td><td>Beximco</td></tr><tr><td>Negachine</td><td>Hor Chen</td></tr><tr><td>NegGram</td><td>Sanofi-Aventis</td></tr><tr><td>Nevigramon</td><td>Sanofi-Aventis</td></tr><tr><td>Unaserus</td><td>Isei</td></tr><tr><td>Wintomylon</td><td>Sanofi Aventis</td></tr><tr><td>Wintorin</td><td>Sankei Yakuhin</td></tr><tr><td>Youdix</td><td>Yoshindo</td></tr><tr><td>Zuno-Nathasid</td><td>Yung Chang</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Abdogyl-N</td><td>Nalidixic Acid and Metronidazole</td></tr><tr><td>Azo-Wintomylon</td><td>Nalidixic Acid and Phenazopiridine</td></tr><tr><td>Azogen</td><td>Nalidixic Acid and Phenazopyridine</td></tr><tr><td>Bactomet</td><td>Nalidixic Acid and Metronidazole</td></tr><tr><td>Bactomet-C</td><td>Nalidixic Acid and Metronidazole</td></tr><tr><td>Gramogyl</td><td>Nalidixic Acid and Metronidazole</td></tr><tr><td>Gramoneg-M</td><td>Nalidixic Acid and Metronidazole</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-bacterial-agents">Anti-Bacterial Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>389-08-2</td></tr><tr><th>Weight</th><td>Average: 232.2353<br>Monoisotopic: 232.08479226</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>MHWLWQUZZRMNGJ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Naphthyridines</td></tr><tr><th>Subclass</th><td>Naphthyridine Carboxylic Acids and Derivatives</td></tr><tr><th>Direct parent</th><td>Naphthyridine Carboxylic Acids and Derivatives</td></tr><tr><th>Alternative parents</th><td>Pyridinecarboxylic Acids; Polyamines; Enolates; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>pyridine carboxylic acid or derivative; pyridine carboxylic acid; pyridine; carboxylic acid derivative; polyamine; enolate; carboxylic acid; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the naphthyridine carboxylic acids and derivatives. These are compounds containing a naphthyridine moiety, where one of the ring atoms bears a carboxylic acid group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of urinary tract infections caused by susceptible gram-negative microorganisms, including the majority of <i>E. Coli</i>, <i>Enterobacter</i> species, <i>Klebsiella</i> species, and <i>Proteus</i> species.</td></tr><tr><th>Pharmacodynamics</th><td>Nalidixic acid is a quinolone antibacterial agent for oral administration. Nalidixic acid has marked antibacterial activity against gram-negative bacteria including <i>Enterobacter</i> species, <i>Escherichia coli</i>, <i>Morganella Morganii</i>; <i>Proteus Mirabilis</i>, <i>Proteus vulgaris</i>, and <i>Providencia rettgeri</i>. <i>Pseudomonas</i> species are generally resistant to the drug. Nalidixic acid is bactericidal and is effective over the entire urinary pH range. Conventional chromosomal resistance to nalidixic acid taken in full dosage has been reported to emerge in approximately 2 to 14 percent of patients during treatment; however, bacterial resistance to nalidixic acid has not been shown to be transferable via R factor.</td></tr><tr><th>Mechanism of action</th><td>Evidence exists for Nalidixic acid that its active metabolite, hydroxynalidixic acid, binds strongly, but reversibly, to DNA, interfering with synthesis of RNA and, consequently, with protein synthesis.</td></tr><tr><th>Absorption</th><td>Following oral administration, nalidixic acid is rapidly absorbed from the gastrointestinal tract. Bioavailability is approximately 96%. Absorption may be delayed if taken with antacids.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Nalidixic acid is 93% bound to protein in the blood, and the active metabolite, hydroxynalidixic acid is 63% bound.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. 30% of administered dose is metabolized to the active metabolite, hydroxynalidixic acid. Rapid conjugation of parent drug and active metabolite to inactive metabolites. Metabolism may vary widely among individuals. In the urine, hydroxynalidixic acid represents 80 to 85% of the antibacterial activity.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Nalidixic Acid</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00887">Hydroxynalidixic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/908">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Following oral administration, NegGram is rapidly absorbed from the gastrointestinal tract, partially metabolized in the liver, and rapidly excreted through the kidneys.
Approximately four percent of NegGram is excreted in the feces.</td></tr><tr><th>Half life</th><td>1.1 to 2.5 hours in healthy adult patients, and up to 21 hours in patients with impaired renal function.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>ORAL (LD<sub>50</sub>): Acute: 1160 mg/kg [Rat]. 572 mg/kg [Mouse]. Toxic psychosis, convulsions, increased intracranial pressure, or metabolic acidosis may occur in patients taking more than the recommended dosage. Vomiting, nausea, and lethargy may also occur following overdosage.</td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9873</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8945</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6315</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5071</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8838</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8566</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8104</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7202</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7888</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8934</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9115</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7834</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9531</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8555</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8815
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.8553
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.0874 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9392
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8534
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Sanofi aventis us llc</li>
<li>Mutual pharmaceutical co inc</li>
<li>Watson laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Professional Co.</li>
<li><a href="http://www.sanofi-aventis.com">Sanofi-Aventis Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB00258">Calcium Acetate</a></td><td>Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as nalidixic acid. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. </td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of warfarin.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with food to reduce irritation. Drink liberally.</li></ul></td></tr></tbody></table>